In summary, MT in the bone cancer pain model was improved at low doses of β-Elemene by modulating NR2B to promote the MOPR expression, thereby inhibiting the expressions of cAMP, p-CaMKII, and CaMKII, which might be a new therapeutic target in the future. This evidence concerns the gene GRIN2B and bone cancer.